Top

Published in:

01-12-2022 | Ketamine | Illicit Drugs in Therapy (A Ross and J Hawthorn, Section Editors)

Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders

Authors: Bradford Martins, Will Rutland, Joao P. De Aquino, Benjamin L. Kazer, Melissa Funaro, Marc N. Potenza, Gustavo A. Angarita

Published in: Current Addiction Reports | Issue 4/2022

Abstract

Purpose of Review

This review summarizes recent clinical trial research on pharmacological treatments for substance use disorders, with a specific focus on agents with potential abuse liability.

Recent Findings

Pharmacological treatments for substance use disorders may include gabapentinoids, baclofen, modafinil, ketamine, cannabinoids, gamma-hydroxybutyrate, and psychedelics. Gabapentinoids may decrease negative subjective effects of withdrawal in alcohol and cannabis use disorders. Cannabinoids similarly appear to decrease use and withdrawal symptoms in cannabis use disorder, while research shows stimulant medications may reduce cravings and increase abstinence in cocaine use disorder. Ketamine and psychedelics may help treat multiple substance use disorders. Ketamine may reduce withdrawal symptoms, promote abstinence, and diminish cravings in alcohol and cocaine use disorders and psychedelics may promote remission, decrease use, and reduce cravings in alcohol and opioid use disorders.

Summary

Regardless of current regulatory approval statuses and potentials for abuse, multiple agents should not be dismissed prematurely as possible treatments for substance use disorders. However, further clinical research is needed before effective implementation can begin in practice.

Available only for authorised users

Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health. 2020;156

Products - vital statistics rapid release - provisional drug overdose data [Internet]. 2022 [cited 2022 Apr 28]. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B. The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology. 2017;124:73–83.PubMedCrossRef

Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiat. 2019;76:208–16.CrossRef

Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv Am Assoc Adv Sci. 2019;5:eaax4043.

Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J. Substance misuse of gabapentin. Br J Gen Pract. 2012;62:406–7.PubMedPubMedCentralCrossRef

Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case–control study. PLOS Medicine Public Library of Science. 2017;14:e1002396.

Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–6.PubMedCrossRef

Das S, Palappalllil DS, Purushothaman ST, Rajan V. An unusual case of baclofen abuse. Indian J Psychol Med. 2016;38:475–6.PubMedPubMedCentralCrossRef

10.

Ghosh S, Bhuyan D. Baclofen abuse due to its hypomanic effect in patients with alcohol dependence and comorbid major depressive disorder. Clinical Psychopharmacology and Neuroscience. Korean College Neuropsychopharmacol. 2017;15:187–9.

11.

Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. CMAJ. 2014;186:1015.PubMedPubMedCentralCrossRef

12.

Morley KC, Logge WB, Fraser I, Morris RW, Baillie AJ, Haber PS. High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. Eur Neuropsychopharmacol. 2021;46:28–36.PubMedCrossRef

13.

• Farokhnia M, Deschaine SL, Sadighi A, Farinelli LA, Lee MR, Akhlaghi F, et al. A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Mol Psychiatry Nature Publishing Group. 2021;26:545–55. This important randomized, double-blind, placebo-controlled study found that baclofen may work in treating AUD by dissociating the link between an initial drink and subsequent alcohol consumption.CrossRef

14.

Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915–22.PubMedCrossRef

15.

Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34:1849–57.PubMedPubMedCentralCrossRef

16.

Müller CA, Geisel O, Pelz P, Higl V, Krüger J, Stickel A, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25:1167–77.PubMedCrossRef

17.

Reynaud M, Aubin H-J, Trinquet F, Zakine B, Dano C, Dematteis M, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol. 2017;52:439–46.PubMedCrossRef

18.

Rigal L, Sidorkiewicz S, Tréluyer J-M, Perrodeau E, Le Jeunne C, Porcher R, et al. Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up. Addiction. 2020;115:1265–76.PubMedCrossRef

19.

Andrade C. Individualized, high-dose baclofen for reduction in alcohol intake in persons with high levels of consumption. J Clin Psychiatry Physicians Postgraduate Press Inc. 2020;81:8187.

20.

Morley KC, Baillie A, Fraser I, Furneaux-Bate A, Dore G, Roberts M, et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2018;212:362–9.PubMedCrossRef

21.

Rombouts SA, Baillie A, Haber PS, Morley KC. Clinical predictors of response to baclofen in the treatment of alcohol use disorder: results from the BacALD trial. Alcohol Alcohol. 2019;54:272–8.PubMedCrossRef

22.

Logge WB, Morris RW, Baillie AJ, Haber PS, Morley KC. Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology. 2021;238:1291–302.PubMedCrossRef

23.

Prisciandaro JJ, Hoffman M, Brown TR, Voronin K, Book S, Bristol E, et al. Effects of gabapentin on dorsal anterior cingulate cortex GABA and glutamate levels and their associations with abstinence in alcohol use disorder: a randomized clinical trial. AJP Am Psychiatric Publish. 2021;178:829–37.CrossRef

24.

Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:70–7.PubMedPubMedCentralCrossRef

25.

Mariani JJ, Pavlicova M, Basaraba C, Mamczur-Fuller A, Brooks DJ, Bisaga A, et al. Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder. Alcoholism Clin Exp Res. 2021;45:1639–52.CrossRef

26.

Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, et al. Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety. Alcohol Clin Exp Res. 2019;43:158–69.PubMed

27.

• Anton RF, Latham P, Voronin K, Book S, Hoffman M, Prisciandaro J, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180:728–36. This important randomized clinical trial showed that gabapentin is effective in promoting abstinence and reducing drinking in individuals with AUD, especially in individuals with withdrawal symptoms.PubMedCrossRef

28.

Krupitsky EM, Rybakova KV, Skurat EP, Semenova NV. Neznanov NG [A double blind placebo controlled randomized clinical trial of the efficacy and safety of pregabalin in induction of remission in patients with alcohol dependence]. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120:33–43.PubMedCrossRef

29.

•• Cheng Y-C, Huang Y-C, Huang W-L. Gabapentinoids for treatment of alcohol use disorder: a systematic review and meta-analysis. Hum Psychopharmacol Clin Exp. 2020;35:e2751. In this important meta-analysis and systematic review of randomized controlled trials comparing the effects of gabapentin and pregabalin on AUD. The authors found that gabapentin had significant effect on percentage of heavy drinking days and alcohol withdrawal symptoms.CrossRef

30.

Strong CE, Kabbaj M. Neural mechanisms underlying the rewarding and therapeutic effects of ketamine as a treatment for alcohol use disorder. Frontiers in Behavioral Neuroscience [Internet]. 2020 [cited 2022 Mar 18];14. Available from: https://www.frontiersin.org/article/https://doi.org/10.3389/fnbeh.2020.593860

31.

•• Worrell SD, Gould TJ. Therapeutic potential of ketamine for alcohol use disorder. Neurosci Biobehav Rev. 2021;126:573–89. This important review summarizes the neural mechanisms of the beneficial effects of ketamine on AUD including AUD comorbid with PTSD and depression. The review compares the overlap in neurobiological characteristics of depression, PTSD, and AUD, and how ketamine affects the often-comorbid nature of these pathologiesPubMedCrossRef

32.

Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. AJP American Psychiatric Publishing. 2020;177:125–33.CrossRef

33.

Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, et al. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179:152–62.PubMedCrossRef

34.

Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry [Internet]. Frontiers; 2018 [cited 2021 Jul 14];9. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fpsyt.2018.00277/full

35.

Pizon AF, Lynch MJ, Benedict NJ, Yanta JH, Frisch A, Menke NB, et al. Adjunct ketamine use in the management of severe ethanol withdrawal. Crit Care Med. 2018;46:e768.PubMedCrossRef

36.

van den Brink W, Addolorato G, Aubin H-J, Benyamina A, Caputo F, Dematteis M, et al. Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addict Biol. 2018;23:969–86.PubMedCrossRef

37.

Skala K, Caputo F, Mirijello A, Vassallo G, Antonelli M, Ferrulli A, et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opinion on Pharmacotherapy. Taylor & Francis. 2014;15:245–57.

38.

Keating GM. Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Investig. 2014;34:63–80.PubMedCrossRef

39.

Caputo F, Vignoli T, Tarli C, Domenicali M, Zoli G, Bernardi M, et al. A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder International Journal of Environmental Research and Public Health. Multidisciplinary Digital Publishing Institute. 2016;13:290.

40.

Leone MA, Vigna‐Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, Ltd; 2010 [cited 2021 Jul 11]; Available from: https://www.cochranelibrary.com/cdsr/doi/https://doi.org/10.1002/14651858.CD006266.pub2/full

41.

Mannucci C, Pichini S, Spagnolo EV, Calapai F, Gangemi S, Navarra M, et al. Sodium oxybate therapy for alcohol withdrawal syndrome and keeping of alcohol abstinence. Curr Drug Metab. 2018;19:1056–64.PubMedCrossRef

42.

Guiraud J, Addolorato G, Aubin H-J, Batel P, de Bejczy A, Caputo F, et al. Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: results of a randomised, double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2021;52:18–30.PubMedCrossRef

43.

Addolorato G, Lesch O-M, Maremmani I, Walter H, Nava F, Raffaillac Q, et al. Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects. Expert Opinion on Drug Safety. Taylor & Francis. 2020;19:159–66.

44.

•• Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience Nature Publishing Group. 2020;21:611–24. This important review summarizes the mechanisms of action of psychedelics with regard to their effects on receptor subsystems, systems-level brain activity and connectivity, and cognitive and emotional processing and how those changes contribute to the potential therapeutic effects of psychedelics on SUD.CrossRef

45.

Mertens LJ, Preller KH. Classical psychedelics as therapeutics in psychiatry – current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry Georg Thieme Verlag KG. 2021;54:176–90.

46.

Morgan C. Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. Curr Opinion in Behav Sci 2017;6

47.

Chi T, Gold JA. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020;411:116715.PubMedCrossRef

48.

Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200–18.PubMedCrossRef

49.

Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:250–8.PubMedCrossRef

50.

DiVito AJ, Leger RF. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. Mol Biol Rep. 2020;47:9791–9.PubMedCrossRef

51.

Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JE. Efficacy tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert review of clinical pharmacology. Taylor & Francis. 2018;11:889–902.

52.

Krebs TS, Johansen P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol SAGE Publications Ltd STM. 2012;26:994–1002.

53.

Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol SAGE Publications Ltd STM. 2019;33:1088–101.

54.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289–99.PubMedCrossRef

55.

Sessa B, Higbed L, O’Brien S, Durant C, Sakal C, Titheradge D, et al. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol. SAGE Publications Ltd STM; 2021;0269881121991792.

56.

Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacol Nature Publishing Group. 2021;46:2250–6.CrossRef

57.

Kumar A, Sharma A, Bansal PD, Bahetra M, Gill HK, Kumar R. A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian J Psychiatry. 2020;62:650–8.PubMedPubMedCentralCrossRef

58.

Tamama K, Lynch MJ. Newly emerging drugs of abuse. Handb Exp Pharmacol. 2020;258:463–502.PubMedCrossRef

59.

Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019;114:1547–55.PubMedPubMedCentralCrossRef

60.

Mariani JJ, Pavlicova M, Choi CJ, Brooks DJ, Mahony AL, Kosoff Z, et al. An open-label pilot study of pregabalin pharmacotherapy for alcohol use disorder. The American Journal of Drug and Alcohol Abuse. Taylor & Francis. 2021;47:467–75.

61.

Schlienz NJ, Lee DC, Stitzer ML, Vandrey R. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend. 2018;187:254–60.PubMedPubMedCentralCrossRef

62.

Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology. 2008;197:157–68.PubMedCrossRef

63.

Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86:22–9.PubMedCrossRef

64.

Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013;128:64–70.PubMedCrossRef

65.

Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116:142–50.PubMedPubMedCentralCrossRef

66.

Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacol. 2013;38:1557–65.CrossRef

67.

Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology. 2016;233:2469–78.PubMedPubMedCentralCrossRef

68.

• Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. Addict Biol. 2019;24:765–76. In this important randomized clinical trial non-treatment seeking cannabis and tobacco users who received nabilone had reduced cannabis withdrawal but no changes in cannabis relapse.PubMedCrossRef

69.

Hill KP, Palastro MD, Gruber SA, Fitzmaurice GM, Greenfield SF, Lukas SE, et al. Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addict. 2017;26:795–801.PubMedPubMedCentralCrossRef

70.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ 9 -tetrahydrocannabinol. Neuropsychopharmacol. 2018;43:142–54.CrossRef

71.

Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. A randomized controlled trial of nabiximols (Sativex®) as an agonist replacement therapy during cannabis withdrawal. JAMA Psychiat. 2014;71:281–91.CrossRef

72.

Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLOS ONE Public Library Sci. 2018;13:e0190768.CrossRef

73.

•• Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland J, McGregor I, et al. Nabiximols for the treatment of cannabis dependence: a randomized clinical trial. JAMA Intern Med. 2019;179:1242–53. This important randomized clinical trial found that participants who received nabiximols had significantly fewer days of illicit cannabis use compared with placebo, and was well tolerated by participants.PubMedPubMedCentralCrossRef

74.

Lintzeris N, Mills L, Dunlop A, Copeland J, Mcgregor I, Bruno R, et al. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial. Drug Alcohol Depend. 2020;215:108220.PubMedCrossRef

75.

Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacol. 2012;37:1689–98.CrossRef

76.

Prisciandaro JJ, Mellick W, Squeglia LM, Hix S, Arnold L, Tolliver BK. Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. Addict Biol. 2022;27:e13085.PubMedCrossRef

77.

Lile JA, Alcorn JL, Hays LR, Kelly TH, Stoops WW, Wesley MJ, et al. Influence of pregabalin maintenance on cannabis effects and related behaviors in daily cannabis users. Experimental and Clinical Psychopharmacology. US: American Psychological Association; 2021;No Pagination Specified-No Pagination Specified.

78.

Azhari N, Hu H, O’Malley KY, Blocker ME, Levin FR, Dakwar E. Ketamine-facilitated behavioral treatment for cannabis use disorder: a proof of concept study. The American Journal of Drug and Alcohol Abuse. Taylor & Francis. 2021;47:92–7.

79.

D’Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry. 2019;6:35–45.PubMedCrossRef

80.

Young KA, Franklin TR, Roberts DC, Jagannathan K, Suh JJ, Wetherill RR, et al. Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues. J Neurosci Soc Neurosci. 2014;34:5038–43.CrossRef

81.

•• Ahmed S, Bachu R, Kotapati P, Adnan M, Ahmed R, Farooq U, et al. Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review. Frontiers in Psychiatry [Internet]. 2019 [cited 2022 Mar 18];10. Available from: https://www.frontiersin.org/article, https://doi.org/10.3389/fpsyt.2019.00228. This important review concluded that gabapentin is effective for mild to moderate acute alcohol withdrawal by reducing cravings, improving the rate of abstinence, and delaying return to heavy drinking. The review also suggests that gabapentin is more effective as an adjunctive medication rather than a monotherapy.

82.

Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Kao UH, Wang P-C, Bholat MA, et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. Journal of addictive diseases. Taylor & Francis. 2008;27:13–23.

83.

Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of general psychiatry. Am Med Assoc. 2006;63:219–28.

84.

Morgan PT, Angarita GA, Canavan S, Pittman B, Oberleitner L, Malison RT, et al. Modafinil and sleep architecture in an inpatient–outpatient treatment study of cocaine dependence. Drug Alcohol Dependence Elsevier. 2016;160:49–56.CrossRef

85.

Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacol Nature Publishing Group. 2008;33:761–8.CrossRef

86.

Malcolm R, Swayngim K, Donovan JL, DeVane CL, Elkashef A, Chiang N, et al. Modafinil and cocaine interactions. The American journal of drug and alcohol abuse. Taylor & Francis. 2006;32:577–87.

87.

Anderson AL, Reid MS, Li S-H, Holmes T, Shemanski L, Slee A, et al. Modafinil for the treatment of cocaine dependence. Drug and alcohol Dependence Elsevier. 2009;104:133–9.CrossRef

88.

Haney M, Rubin E, Denson RK, Foltin RW. Modafinil reduces smoked cocaine self-administration in humans: effects vary as a function of cocaine ‘priming’ and cost. Drug Alcohol Depend. 2021;221:108554.PubMedPubMedCentralCrossRef

89.

Kampman KM, Lynch KG, Pettinati HM, Spratt K, Wierzbicki MR, Dackis C, et al. A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug and alcohol Dependence Elsevier. 2015;155:105–10.CrossRef

90.

Schmitz JM, Green CE, Stotts AL, Lindsay JA, Rathnayaka NS, Grabowski J, et al. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa–carbidopa, naltrexone. Drug Alcohol Depend. 2014;136:100–7.PubMedPubMedCentralCrossRef

91.

Sangroula D, Motiwala F, Wagle B, Shah VC, Hagi K, Lippmann S. Modafinil treatment of cocaine dependence: a systematic review and meta-analysis. Substance Use & Misuse. Taylor & Francis. 2017;52:1292–306.

92.

Mooney ME, Herin DV, Specker S, Babb D, Levin FR, Grabowski J. Pilot study of the effects of lisdexamfetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Dependence Elsevier. 2015;153:94–103.CrossRef

93.

Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W, Hendriks VM. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. The Lancet. 2016;387:2226–34.CrossRef

94.

•• Chan B, Freeman M, Ayers C, Korthuis PT, Paynter R, Kondo K, et al. A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. Drug Alcohol Depend. 2020;216:108193. This important review and meta-analysis found low-strength evidence that psychostimulants (mazindol and dexamphetamine) may reduce cocaine use, though the difference was not statistically significant, as well as moderate-strength evidence that antidepressants (desipramine, bupropion, and fluoxetine) worsened retention of opioid maintenance therapy.PubMedPubMedCentralCrossRef

95.

Levin FR, Bisaga A, Raby W, Aharonovich E, Rubin E, Mariani J, et al. Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. J Subst Abus Treat Oxford Pergamon-Elsevier Science Ltd. 2008;34:80–9.CrossRef

96.

Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007;87:20–9.PubMedCrossRef

97.

Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry Am Med Assoc. 2015;72:593–602.CrossRef

98.

Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry Elsevier. 2014;76:40–6.CrossRef

99.

Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. AJP Am Psychiatric Publishing. 2019;176:923–30.CrossRef

100.

Dakwar E, Nunes EV, Hart CL, Hu MC, Foltin RW, Levin FR. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270–6.PubMedPubMedCentralCrossRef

101.

Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder—a systematic review and meta-analysis. J Gen Intern Med. 2019;34:2858–73.PubMedPubMedCentralCrossRef

102.

Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23:273–83.PubMedCrossRef

103.

Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39:13–9.PubMedCrossRef

104.

Bouida W, Bel Haj Ali K, Ben Soltane H, Msolli MA, Boubaker H, Sekma A, et al. Effect on opioids requirement of early administration of intranasal ketamine for acute traumatic pain. Clin J Pain. 2020;36:458–62.PubMedCrossRef

105.

Nielsen RV, Fomsgaard JS, Nikolajsen L, Dahl JB, Mathiesen O. Intraoperative S-ketamine for the reduction of opioid consumption and pain one year after spine surgery: a randomized clinical trial of opioid-dependent patients. Eur J Pain. 2019;23:455–60.PubMedCrossRef

106.

Boenigk K, Echevarria GC, Nisimov E, von Bergen Granell AE, Cuff GE, Wang J, et al. Low-dose ketamine infusion reduces postoperative hydromorphone requirements in opioid-tolerant patients following spinal fusion: a randomised controlled trial. Eur J Anaesthesiol EJA. 2019;36:8–15.CrossRef

107.

Nielsen RV, Fomsgaard JS, Siegel H, Martusevicius R, Nikolajsen L, Dahl JB, et al. Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded trial. Pain. 2017;158:463–70.PubMedCrossRef

108.

Pisano VD, Putnam NP, Kramer HM, Franciotti KJ, Halpern JH, Holden SC. The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol SAGE Publications Ltd STM. 2017;31:606–13.

109.

Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psychiatry. 2020;10:955.PubMedPubMedCentralCrossRef

110.

Argento E, Braschel M, Walsh Z, Socias ME, Shannon K. The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. J Psychopharmacol SAGE Publications Ltd STM. 2018;32:1385–91.

111.

Brown T. Ibogaine In The treatment of substance dependence. Current drug abuse reviews. 2013;6.

112.

Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse Taylor Francis. 2018;44:24–36.CrossRef

113.

D’Souza DC, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, et al. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Mol Psychiatry. 2021;26:3192–200.PubMedCrossRef

114.

Angarita GA, Worhunsky PD, Naganawa M, Toyonaga T, Nabulsi NB, Li C-SR, et al. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: an exploratory 11 C-UCB-J positron emission tomography study in humans. Addict Biol. 2022;27:e13123.PubMedCrossRef

Title: Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders
Authors: Bradford Martins
Will Rutland
Joao P. De Aquino
Benjamin L. Kazer
Melissa Funaro
Marc N. Potenza
Gustavo A. Angarita
Publication date: 01-12-2022
Publisher: Springer International Publishing
Keywords: Ketamine
Gabapentin
Cannabinoid
Opioids
Opioids
Published in: Current Addiction Reports / Issue 4/2022
Electronic ISSN: 2196-2952
DOI: https://doi.org/10.1007/s40429-022-00432-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2022

Treatment of Alcohol Use Problems Among Rural Populations: a Review of Barriers and Considerations for Increasing Access to Quality Care

THC, CBD, and Anxiety: a Review of Recent Findings on the Anxiolytic and Anxiogenic Effects of Cannabis’ Primary Cannabinoids

Estimation of Behavioral Addiction Prevalence During COVID-19 Pandemic: A Systematic Review and Meta-analysis

Impact of Food Addiction in Therapy Response in Obesity and Eating Disorders

A Review of Disparities in Cannabis Use and Cannabis Use Disorder Affecting Sexual and Gender Minority Populations and Evidence for Contributing Factors

Potential Influences of the Darknet on Illicit Drug Diffusion